K. Balamurugan, HIF-1 at the crossroads of hypoxia, inflammation, and cancer, International Journal of Cancer, vol.35, issue.2011, pp.1058-1066, 2016.
DOI : 10.1002/ijc.29519

E. Baldini, S. Sorrenti, E. D-'armiento, D. Matteo, F. M. Catania et al., The urokinase plasminogen activating system in thyroid cancer: clinical implications, G. Chir, issue.10, pp.33-305, 2012.

M. R. Pelizzo, M. Rugge, F. Mantero, D. Nacamulli, M. E. Girelli et al., BRAF in primary and recurrent papillary thyroid cancer: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability, Eur. J. Endocrinol, vol.163, issue.4, pp.659-663, 2010.

M. Bonicalzi, I. Groulx, N. De-paulsen, and S. Lee, Role of Exon 2-encoded ??-Domain of the von Hippel-Lindau Tumor Suppressor Protein, Journal of Biological Chemistry, vol.276, issue.2, pp.1407-1416, 2001.
DOI : 10.1074/jbc.M008295200

C. Cassol and O. Mete, Endocrine Manifestations of von Hippel???Lindau Disease, Archives of Pathology & Laboratory Medicine, vol.139, issue.2, 2015.
DOI : 10.5858/arpa.2013-0520-RS

M. G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou et al., Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, European Journal of Endocrinology, vol.165, issue.3, 2011.
DOI : 10.1530/EJE-11-0466

F. Chesnel, P. Hascoet, J. P. Gagné, A. Couturier, F. Jouan et al., The von Hippel???Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform, British Journal of Cancer, vol.55, issue.2, pp.336-344
DOI : 10.1073/PNAS.95.15.8817
URL : https://hal.archives-ouvertes.fr/hal-01162377

P. Chomczynsky and P. Sacchi, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Analytical Biochemistry, vol.162, issue.1, pp.156-159, 1987.
DOI : 10.1016/0003-2697(87)90021-2

L. Davies and H. Welch, Increasing Incidence of Thyroid Cancer in the United States, 1973-2002, JAMA, vol.295, issue.18, pp.2164-2167, 1973.
DOI : 10.1001/jama.295.18.2164

J. Gnarra, K. Tory, Y. Weng, L. Schmidt, M. Wei et al., Mutations of the VHL tumour suppressor gene in renal carcinoma, Nature Genetics, vol.88, issue.1, pp.85-90, 1994.
DOI : 10.1038/ng0594-85

S. Grebe, B. Mciver, I. Hay, P. Wu, L. Maciel et al., Frequent Loss of Heterozygosity on Chromosomes 3p and 17p without VHL or p53 Mutations Suggests Involvement of Unidentified Tumor Suppressor Genes in Follicular Thyroid Carcinoma, Journal of Clinical Endocrinology & Metabolism, vol.82, issue.11, pp.3684-3691, 1997.
DOI : 10.1210/jc.82.11.3684

D. Handkiewicz-junak, A. Czarniecka, and B. Jarz?b, Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions, Molecular and Cellular Endocrinology, vol.322, issue.1-2, pp.8-28, 2010.
DOI : 10.1016/j.mce.2010.01.007

C. Hedinger, E. Williams, and L. Sobin, The WHO histological classification of thyroid tumors: A commentary on the second edition, Cancer, vol.9, issue.5, pp.908-911, 1989.
DOI : 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I

J. Hunt, J. Yim, M. Tometsko, S. Finkelstein, P. Swalsky et al., Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors, Surgery, vol.134, issue.6, pp.1043-1048, 2003.
DOI : 10.1016/j.surg.2003.07.023

O. Iliopoulus, M. Ohh, and K. Jrwg, pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation, Proceedings of the National Academy of Sciences, vol.92, issue.20, pp.11661-11666, 1998.
DOI : 10.1073/pnas.89.10.4226

A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu et al., Cancer Statistics, 2009, CA: A Cancer Journal for Clinicians, vol.59, issue.4, pp.225-249, 2009.
DOI : 10.3322/caac.20006

B. Kinder, Well differentiated thyroid cancer, Current Opinion in Oncology, vol.15, issue.1, pp.71-77, 2003.
DOI : 10.1097/00001622-200301000-00011

F. Latif, K. Tory, J. Gnarra, M. Yao, F. Duh et al., Identification of the von Hippel-Lindau disease tumor suppressor gene, Science, vol.260, issue.5112, pp.1317-1320, 1993.
DOI : 10.1126/science.8493574

M. Los, G. Jansen, W. Kaelin, C. Lips, G. Blijham et al., Expression pattern of the von Hippel-Lindau protein in human tissue, Lab Invest, vol.75, pp.231-238, 1996.

E. Maher, H. Neumann, and S. Richard, von Hippel???Lindau disease: A clinical and scientific review, European Journal of Human Genetics, vol.62, issue.6, pp.617-623, 2011.
DOI : 10.2174/1566524043359827
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110036

Y. Nikiforov, P. Biddinger, and L. Thompson, Diagnostic pathology and molecular genetics of the thyroid, p.381, 2009.

J. Pasieka, Anaplastic thyroid cancer, Current Opinion in Oncology, vol.15, issue.1, pp.78-83, 2003.
DOI : 10.1097/00001622-200301000-00012

K. Patel and A. Shaha, Poorly differentiated and anaplastic thyroid cancer, Cancer Control, vol.13, pp.119-128, 2006.

F. Richards, P. Schofield, S. Fleming, and E. Maher, Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis, Human Molecular Genetics, vol.5, issue.5, pp.639-644, 1996.
DOI : 10.1093/hmg/5.5.639

C. Robinson and M. Ohh, The multifaceted von Hippel-Lindau tumor suppressor protein, 2014.
DOI : 10.1016/j.febslet.2014.02.026
URL : http://doi.org/10.1016/j.febslet.2014.02.026

A. Rodrigues-serpa, A. Catarino, and J. Soares, Loss of heterozygosity in follicular and papillary thyroid carcinomas, Cancer Genetics and Cytogenetics, vol.141, issue.1, pp.26-31, 2003.
DOI : 10.1016/S0165-4608(02)00686-6

A. Schoenfeld, E. Davidowitz, and R. Burk, A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor, Proceedings of the National Academy of Sciences, vol.66, issue.6, pp.8817-8822, 1998.
DOI : 10.1016/0092-8674(91)90033-U
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC21160/pdf

B. Stanojevic, V. Saenko, L. Todorovic, N. Petrovic, D. Nikolic et al., Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma, PLoS ONE, vol.2, issue.12, p.114511, 2015.
DOI : 10.1371/journal.pone.0114511.s002

D. Antoni, E. , D. Armiento, M. Frati, and L. , High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma, J Clin Endocrinol Metab, vol.96, pp.504-508, 2011.

J. Vandesompele, D. Preter, K. Pattyn, F. Poppe, B. et al., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, vol.3, p.34, 2002.